» Articles » PMID: 10649981

Esterase-sensitive Nitric Oxide Donors of the Diazeniumdiolate Family: in Vitro Antileukemic Activity

Overview
Journal J Med Chem
Specialty Chemistry
Date 2000 Jan 29
PMID 10649981
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

We have designed a novel prodrug class that is stable in neutral aqueous media but releases bioactive nitric oxide (NO) on metabolism by esterase. Diazeniumdiolates of structure R(2)N-N(O)=N-OR', in which R' = Na, were reacted with BrCH(2)OAc to convert the spontaneously NO-releasing salts 1a (R(2)N = diethylamino) and 1b (R(2)N = pyrrolidino) to prodrugs 2a (AcOM-DEA/NO) and 2b (AcOM-PYRRO/NO), respectively, where R' = CH(2)OAc. In contrast to anions 1a and 1b (half-lives in pH 7.4 phosphate at 37 degrees C of 2 min and 3 s, respectively), 2a and 2b showed only minimal decomposition after 16 h under these conditions. Very rapid hydrolysis occurred in the presence of porcine liver esterase, however, with free anion 1a being observed as an intermediate in the esterase-induced generation of NO from 2a. The potential utility of this prodrug class is illustrated with a comparison of 1 and 2 as antiproliferative agents in NO-sensitive human leukemia cell lines HL-60 and U937. While the 72-h IC(50)'s for 1a and 1b (which generate NO throughout the medium) in HL-60 cell cultures were >600 microM, those of 2a and 2b were 8.3 and 6.4 microM, respectively. This result is consistent with our hypothesis that 2 is selectively hydrolyzed to 1 and thence to NO intracellularly. For U937 cells, the 72-h IC(50) for both 2a and 2b was 53 microM. By contrast, relatively high antiproliferative IC(50)'s (>100 microM in U937 cells) were observed for analogues in which R' = CH(2)CH(2)SC(O)Me, from which acetyl and 2-mercaptoethyl groups must be successively cleaved to free the NO-releasing diazeniumdiolate function. Within 24 h at initial concentrations of 50 microM, 2a and 2b induced apoptosis in 50% and 57% of the HL-60 cells, respectively (35% and 40% of the U937 cells, respectively). The data reveal significant in vitro antileukemic activity on the part of these novel compounds. Moreover, their substantial ease-of-handling advantages over the anionic diazeniumdiolates from which they are derived suggest their use as convenient agents for probing the biological roles of NO.

Citing Articles

Ibuprofen‑derived nitric oxide donors with a high affinity to human serum albumin induce cell death in pancreatic cancer cells through a non‑caspase 3/7‑mediated pathway.

Nishi K, Arimura Y, Suetsugi N, Beppu T, Takasaki K, Tamori A Biomed Rep. 2024; 21(5):159.

PMID: 39268409 PMC: 11391177. DOI: 10.3892/br.2024.1847.


Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications.

Tabish T, Crabtree M, Townley H, Winyard P, Lygate C JACC Basic Transl Sci. 2024; 9(5):691-709.

PMID: 38984042 PMC: 11228123. DOI: 10.1016/j.jacbts.2023.07.017.


Therapeutic gas-releasing nanomedicines with controlled release: Advances and perspectives.

Opoku-Damoah Y, Zhang R, Ta H, Xu Z Exploration (Beijing). 2023; 2(5):20210181.

PMID: 37325503 PMC: 10190986. DOI: 10.1002/EXP.20210181.


Heavy metal toxicity in plants and the potential NO-releasing novel techniques as the impending mitigation alternatives.

Pande A, Mun B, Methela N, Rahim W, Lee D, Lee G Front Plant Sci. 2022; 13:1019647.

PMID: 36267943 PMC: 9578046. DOI: 10.3389/fpls.2022.1019647.


Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.

Kim J, Thomas S Pharmacol Rev. 2022; 74(4):1146-1175.

PMID: 36180108 PMC: 9553106. DOI: 10.1124/pharmrev.121.000500.